Search Results

121 - 130 of 358 items :

  • pharmacokinetics x
Clear All
Cognitive Impairment in Schizophrenia, Neurotransmitters and the New Atypical Antipsychotic Aripiprazole

’s essential psychopharmacology: the prescriber’s guide. Antidepressants 4th ed. New York; Cambridge University Press; 2011:22. 24. Kubo M, Koue T, Maune H, et al. Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab Pharmacokinet 2007;22(5):358-66. 25. Burstein ES, Ma J, Wong S, et al. Intrinsic Efficacy of Antipsychotics at Human D2, D3, and D4 Dopamine Receptors: Identification of the Clozapine Metabolite N-Desmethylclozapine as a D2/D

Open access
Original Article. Study of the cytotoxic/toxic potential of the novel anticancer selenodiazoloquinolone on fibroblast cells and 3D skin model

-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. Antimicrobiol Agents Chemother 54: 411-417. Jantová S, Letašiová S, Koňariková K, Milata V, Brezová V. (2010). Eff ect of new synthetically prepared quinolone ethyl-1,4-dihydro-8-nitro-4-oxoquinoline-3-carboxylate on human leukemia cell line HL-60 without/with presence of UVA irradiation. Acta Chimica Slovaca 3: 51-72. Jantová S, Koňariková K, Letašiová S, Paulovičová E, Milata V, Brezová V. (2011). Photochemical and phototoxic properties of

Open access
Sevoflurane and isoflurane genotoxicity in kidney cells of mice

E, Im H, Mun J, Yang M, Khim JY, Lee E, Lim SH, Kong MH, Lee M, Sul D. Oxidative damages in the DNA, lipids, and proteins of rats exposed to isofluranes and alcohols. Toxicology 2006;220:169-78. doi: 10.1016/j.tox.2005.12.010 25. Behne M, Wilke HJ, Harder S. Clinical pharmacokinetics of sevoflurane. Clin Pharmacokinet 1999;36:13-26. doi: 10.2165/00003088-199936010-00002 26. Hase K, Meguro K, Nakamura T. Effects of sevoflurane anesthesia combined with epidural block on renal function in the elderly: comparison with isoflurane. J

Open access
Aldose reductase inhibitory activity and antioxidant capacity of pomegranate extracts

from tunisian pomegranate (Punica granatum). Fruits Journal of Food Science   76 : C707-C713. Wang R, Ding Y, Liu R, Xiang L, Du L. (2010). Pomegranate: constituents, bioactivities and pharmacokinetics. fruit, Vegetable and Cereal Science and Biotechnology Special Issue 2 : 77-87. Yabe-Nishimura C. (1998). Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol Rev   50 : 21-33. Zahin M, Aqil F, Ahmad I. (2010). Broad spectrum

Open access
Ovarian cancer: early detection, angiogenesis, lymphangiogenesis and current prospects for therapy

target antigens for immunodiagnosis and immunotherapy in ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 1990;36:221-8. 41. Coliva A, Zacchetti A, Luison E, et. al. 90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas. Cancer Immunol Immunother. 2005;54:1200-13. 42. Rosenblum M, Shawver L, Marks J, et. al. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft

Open access
Urethritis and antimicrobial resistance

(1):6-8. 27. Golparian D, Fernandes P, Ohnishi M, Jensen JS, Unemo M. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with various high-level antimicrobial resistance: potential treatment option for gonorrhea? Antimicrob Agents Chemother 2012;56(5):2739-42. 28. Still JG, Schranz J, Degenhardt TP, Scott D, Fernandes P, Gutierrez MJ, et al. Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses

Open access
The association between the OPRM1 A118G polymorphism and addiction in a Turkish population

polymorphisms of the mu opioid receptor in methamphetamine abusers. Ann N Y Acad Sci 2004;1025:316–24. doi: 10.1196/annals.1316.039 32. Ginosar Y, Davidson EM, Meroz Y, Blotnick S, Shacham M, Caraco Y. Mu-opioid receptor (A118G) single-nucleotide polymorphism affects alfentanil requirements for extracorporeal shock wave lithotripsy: a pharmacokinetic – pharmacodynamic study. Br J Anaesth 2009;103:420–7. doi: 10.1093/bja/aep192 33. Kumar D, Chakraborty J, Das S. Epistatic effects between variants of kappa-opioid receptor gene and A118G of muopioid receptor gene

Open access
Clinical and Economic Outcomes of New Oral Anticoagulants in Orthopaedics

.1302/0301-620X.90B2.20106. 8. Bass AR. (2015). Using new oral anticoagulants in patients undergoing major orthopedic surgery. Curr Rheumatol Rep. 17(4), 25. DOI: 10.1007/s11926-015-0498-z. 9. Eriksson BI, Quinlan DJ, Weitz JI. (2009). Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 48(1), 1-22. DOI: 10.2165/0003088-200948010-00001. 10. Wong PC, Crain EJ, Pinto DJ, Watson CA. (2007). Dose-Dependent Antithrombotic Effects of Apixaban, an Oral Direct Factor Xa Inhibitor, in

Open access
Local Anesthesia in Pediatric Patients – a Review of Current and Alternative Methods, Devices and Techniques

;25(3):215-9. 8. Peedikayil F, Vijayan A. An update on local anesthesia for pediatric dental patients. Anesth Essays Res 2013;7(1):4-9. 9. Meechan JG, Donaldson D. The intraoral use of EMLA cream in children: a clinical investigation. ASDC J Dent Child 61(4):260-2. 10. Ciancio SG, Hutcheson MC, Ayoub F, et al. Safety and efficacy of a novel nasal spray for maxillary dental anesthesia. J Dent Res 2013;92(7 Suppl): 43S-8S. 11. Giannakopoulos H, Levin LM, Chou JC, et al. The cardiovascular effects and pharmacokinetics of intranasal tetracaine plus oxymetazoline

Open access
Genetic Polymorphism of Metabolic Enzymes P450 (CYP) as a Susceptibility Factor for Drug Response, Toxicity, and Cancer Risk

cancer among cigarette smokers in a Chinese population. Pharmacogenet Genomics 2009;19:25--34. Houston JB, Galetin A. Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr Drug Metab 2008;9:940--51. Hyland R, Dickins M, Collins C, Jones H, Jones B. Maraviroc: in vitro assessment of drug-drug interaction potential. Br J Clin Pharmacol 2008;66:498--507. Youdim KA, Zayed A, Dickins M, Phipps A, Griffiths M, Darekar A, Hyland R, Fahmi O, Hurst S

Open access